-       Report 
   - August 2024
    -  80 Pages 
    Japan
   
   From       €3141EUR$3,500USD£2,756GBP 
                -       Report 
   - July 2024
    -  182 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                -       Report 
   - January 2025
    -  85 Pages 
    India
   
   From       €3141EUR$3,500USD£2,756GBP 
                  -       Report 
   - July 2024
    -  150 Pages 
    Global
   
   From       €2692EUR$3,000USD£2,363GBP 
      €3365EUR$3,750USD£2,953GBP 
                -       Report 
   - March 2024
    -  200 Pages 
    Global
   
   From       €3724EUR$4,150USD£3,268GBP 
                 -       Report 
   - January 2024
    -  200 Pages 
    Global
   
   From       €3724EUR$4,150USD£3,268GBP 
                -       Report 
   - January 2024
    -  200 Pages 
    Global
   
   From       €3724EUR$4,150USD£3,268GBP 
                -       Report 
   - October 2023
    -  145 Pages 
    Global
   
   From       €2827EUR$3,150USD£2,481GBP 
                -       Report 
   - July 2024
    -  105 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - November 2023
    -  125 Pages 
    Africa, Middle East
   
   From       €3096EUR$3,450USD£2,717GBP 
                -       Report 
   - November 2023
    -  120 Pages 
    
   From       €3096EUR$3,450USD£2,717GBP 
                -       Report 
   - February 2023
    -  206 Pages 
    Global
   
   From       €3993EUR$4,450USD£3,505GBP 
                -       Report 
   - July 2024
    -  118 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - February 2024
    -  110 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - February 2024
    -  110 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - August 2024
    -  200 Pages 
    Global
   
   From       €3472EUR$3,869USD£3,047GBP 
                -       Report 
   - May 2023
    -  140 Pages 
    Global
   
   From       €4441EUR$4,949USD£3,898GBP 
                  -       Report 
   - October 2023
    -  150 Pages 
    Global
   
   From       €3455EUR$3,850USD£3,032GBP 
      €4352EUR$4,850USD£3,820GBP 
                  -       Report 
   - April 2023
    -  150 Pages 
    Global
   
   From       €3455EUR$3,850USD£3,032GBP 
      €4352EUR$4,850USD£3,820GBP 
                -       Report 
   - January 2024
    -  140 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
             
         The iPS Cell market is a rapidly growing sector within the pharmaceutical industry. It is based on the use of induced pluripotent stem cells (iPSCs) to develop treatments for a variety of diseases. iPSCs are derived from adult cells, such as skin or blood cells, and are reprogrammed to become pluripotent stem cells. These cells can then be used to create a variety of cell types, such as neurons, heart cells, and liver cells, which can be used to study diseases and develop treatments.
The iPS Cell    market is driven by the increasing demand for personalized medicine, as well as the potential for iPSCs to be used in regenerative medicine. Additionally, the use of iPSCs in drug discovery and development is becoming increasingly popular, as it allows for the testing of drugs on human cells in a laboratory setting.
Some of the major players in the iPS Cell market include Cellular Dynamics International, Takara Bio, ReproCELL, and Axol Bioscience. Additionally, a number of biotechnology companies, such as Novocell and Pluristem, are also developing iPSC-based treatments. Show Less   Read more